Format

Send to

Choose Destination
Brain Lang. 2015 Mar;142:45-53. doi: 10.1016/j.bandl.2015.01.009. Epub 2015 Feb 3.

Clinical and neuroimaging biomarkers of amyloid-negative logopenic primary progressive aphasia.

Author information

1
Department of Radiology, Mayo Clinic, Rochester, MN, United States. Electronic address: whitwell.jennifer@mayo.edu.
2
Department of Neurology (Division of Speech Pathology), Mayo Clinic, Rochester, MN, United States.
3
Department of Psychiatry and Psychology (Neuropsychology), Mayo Clinic, Rochester, MN, United States.
4
Department of Radiology, Mayo Clinic, Rochester, MN, United States; Department of Information Technology, Mayo Clinic, Rochester, MN, United States.
5
Department of Radiology, Mayo Clinic, Rochester, MN, United States.
6
Department of Neuroscience, Mayo Clinic, Jacksonville, FL, United States.
7
Department of Neurology (Division of Behavioral Neurology), Mayo Clinic, Rochester, MN, United states.

Abstract

Logopenic primary progressive aphasia (lvPPA) is a progressive language disorder characterized by anomia, difficulty repeating complex sentences, and phonological errors. The majority, although not all, lvPPA patients have underlying Alzheimer's disease. We aimed to determine whether clinical or neuroimaging features differ according to the deposition of Aβ on Pittsburgh-compound B PET in lvPPA. Clinical features, patterns of atrophy on MRI, hypometabolism on FDG-PET, and white matter tract degeneration were compared between six PiB-negative and 20 PiB-positive lvPPA patients. PiB-negative patients showed more asymmetric left-sided patterns of atrophy, hypometabolism and white matter tract degeneration, with greater left anteromedial temporal and medial prefrontal involvement, than PiB-positive patients. PiB-positive patients showed greater involvement of right temporoparietal and frontal lobes. There was very little evidence for clinical differences between the groups. Strikingly asymmetric neuroimaging findings with relatively preserved right hemisphere may provide clues that AD pathology is absent in lvPPA.

KEYWORDS:

Beta-amyloid; FDG-PET; Logopenic; Magnetic resonance imaging; Pittsburgh compound B; Primary progressive aphasia; Progranulin

PMID:
25658633
PMCID:
PMC4380294
DOI:
10.1016/j.bandl.2015.01.009
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center